Biosimilars Provision In Pacific Trade Deal Adds Fuel To Generic Fight
This article was originally published in The Pink Sheet Daily
Executive Summary
As negotiations over Trans-Pacific Partnership Agreement near completion, generic drug advocates make all-out push to eliminate IP provisions, particularly one they say would create patent linkage for biologics.
You may also be interested in...
India-Style Patent Laws Targeted In Trans-Pacific Trade Negotiations
Draft intellectual property chapter of the Trans-Pacific Partnership includes a provision prohibiting signatories from denying patents solely because a product did not show enhanced efficacy over a known product.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.